CogniTOT by Liltoda Selected as Winner of the i4KIDS-4RARE Neuroepilepsy Innovation Programme 

The European project i4KIDS-4RARE, coordinated by i4KIDS, is pleased to announce that CogniTOT, developed by Liltoda Ltd, has been selected as the winning solution of the i4KIDS-4RARE Neuroepilepsy Innovation Programme, an initiative developed in collaboration with EpiCARE, the European Reference Network for Rare and Complex Epilepsies.

The programme aims to identify and accelerate innovative solutions addressing unmet clinical needs in paediatric rare epilepsies, particularly in the areas of early cognitive impairment detection, neurodevelopmental monitoring, and personalised patient care. Following an evaluation process conducted by a multidisciplinary panel of clinical and innovation experts, CogniTOT was selected for its strong scientific evidence, clinical relevance, and readiness for implementation within European paediatric healthcare settings.

Developed by Liltoda Ltd and based on more than a decade of research conducted at the INFANT Research Centre at University College Cork, CogniTOT is a language-independent digital cognitive assessment tool designed for toddlers aged 18 to 30 months. The solution has been validated in more than 1,000 children across ten countries and enables the early identification of cognitive developmental difficulties through a standardised, evidence-based approach. Its design allows for implementation across different linguistic and cultural settings, increasing access to early cognitive screening tools. The project addresses a significant healthcare challenge. Today, more than half of children with learning difficulties are not diagnosed before reaching school age, reducing opportunities for early intervention and potentially affecting long-term developmental outcomes. For children living with rare epilepsies and other complex neurological disorders, the early identification of cognitive difficulties is particularly important to support clinical decision-making and personalised care planning.

As part of the i4KIDS-4RARE Neuroepilepsy Innovation Programme, CogniTOT will now enter a pilot phase within one of the paediatric centres of the EpiCARE network. The pilot will assess the tool’s potential to facilitate the early detection and monitoring of cognitive impairment in children affected by rare epilepsies, contributing to more personalised care pathways and improved long-term outcomes. The call attracted significant interest from innovative organisations across Europe. The proposals received demonstrated the strength of the European innovation ecosystem in addressing unmet needs in paediatric rare diseases and highlighted the importance of fostering collaboration between researchers, clinicians, companies, and patient organisations.

The Neuroepilepsy Innovation Programme is implemented within the framework of the European project i4KIDS-4RARE, which aims to accelerate the development, validation, and adoption of innovative solutions for paediatric rare diseases through collaboration among healthcare professionals, researchers, companies, patients, and institutions across Europe. This project has received funding from the European Union’s EU4Health Programme.

For more information about CogniTOT, visit: https://cognitot.com